Hepatitis C

Type: Keyphrase
Name: Hepatitis C
First reported 23 mins ago - Updated 23 mins ago - 1 reports

Madness star supports hep C charity

Tuesday 16th September 2014Madness star Cathal Smyth will unveil his debut solo album at a fundraising gig in aid of The Hepatitis C Trust.Smyth, also known as Chas Smash, will perform his album A Comfortable Man at Wilton's Music Hall, in London's East ... [Published Media Trust - 23 mins ago]
First reported 27 mins ago - Updated 27 mins ago - 1 reports

Research and Markets: Global Hepatitis C Market Report 2014-2018: Leading Vendors are F. Hoffmann-La Roche, Gilead Sciences, J&J, Merck & Vertex Pharmaceuticals

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/92nqsp/global_hepatitis) has announced the addition of the "Global Hepatitis C Market 2014-2018" report to their offering. The Global Hepatitis C market to grow ... [Published Business Wire Health News - 27 mins ago]
First reported Sep 15 2014 - Updated 51 mins ago - 42 reports

One Of The Most Expensive Pills In The World Is About To Get Cheaper In Poor Countries

Hepatitis C medication Sovaldi CREDIT: AP Photo/Courtesy of Gilead Sciences, File The company that makes one of the most expensive pills the world is attempting to expand access to the medication among low-income people who can’t afford the $1,000 ... [Published Think Progress - 51 mins ago]
First reported 3 hours ago - Updated 3 hours ago - 1 reports

Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

&am...Renub Research ... [Published PharmiWeb - 3 hours ago]
First reported 10 hours ago - Updated 7 hours ago - 5 reports

Cipla enters into non-exclusive licensing agreement with Gilead

Cipla, a global pharmaceutical company, has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for manufacturing and distribution of Sofosbuvir mono, Ledipasvir mono, the fixed-dose combination of Ledipasvir/Sofosbuvir with each other ... [Published Indian-Commodity - 7 hours ago]
First reported Sep 15 2014 - Updated 11 hours ago - 4 reports

Access to new drugs could save 350 lives from hep C

Three hundred and fifty people seriously ill with hepatitis C need early access to new therapies that could save their lives, according to the Irish Haemophilia Society (IHS). ... [Published IrishExaminer.com - Ireland - 11 hours ago]
Entities: Hemophilia, Hepatitis C
First reported Sep 15 2014 - Updated 11 hours ago - 2 reports

New 'life saving' drugs for Hep C sufferers

New "life saving" drugs which cost €45,000 per patient, and have a 95pc success rate, should be made available to Hepatitis C sufferers with only months to live. ... [Published Irish Independent - 11 hours ago]
Entities: Hepatitis C
First reported Sep 14 2014 - Updated 18 hours ago - 7 reports

Gilead, maker of Hepatitis C drug, strikes deal on generics for poor countries

NEW DELHI — The maker of one of the costliest drugs in the world announced Monday that it had struck agreements with seven Indian generic drugmakers to sell lower-cost versions of the medicine — a $1,000-a-pill Hepatitis C treatment — in poorer count ... [Published Santa Fe New Mexican - 18 hours ago]
First reported 21 hours ago - Updated 20 hours ago - 2 reports

Should Direct-Acting Antiviral Agents Replace the Standard of Care for Hepatitis C Infection?

For the 3.2 million people in the United States infected with the hepatitis C virus, disease management can be costly and debilitating. But are the new agents recently approved by the Food and Drug Administration (FDA) a better way to manage the disease? ... [Published Bio-Medicine - 20 hours ago]
First reported Sep 14 2014 - Updated 23 hours ago - 41 reports

Mylan, Ranbaxy, others to bring cheap Sovaldi to 91 markets

Gilead's Sovaldi--Courtesy of GileadCheap Sovaldi is on the way, and it could very well be coming to an emerging market near you. Gilead ($GILD) has ironed out a licensing deal for the hep C wonder with 7 companies--including Mylan ($MYL) and Ranbaxy--and ... [Published FiercePharma - 23 hours ago]
First reported Sep 15 2014 - Updated Sep 15 2014 - 2 reports

Alios BioPharma Presents Data on Its Anti-HCV Nucleotide AL-335 at Special Conference on Hepatitis C

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/15/14 -- Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, presented the preclinical profile of one of its wholly-owned anti-hepatitis C virus (HCV) nucleotides ... [Published RCL Advisors - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Methadone driving down hepatitis C rates

Methadone treatment is dramatically curbing hepatitis C rates among people who inject drugs, Australian research shows.Opioid substitution therapy was linked to a more than a fivefold reduced risk of hepatitis C among people who inject drugs , especially ... [Published Australian Doctor - Sep 15 2014]

Quotes

"Just know that there is a real risk of infection. It's not just this type of infection, these micro bacteria, but there are reports of Hepatitis C being transmitted because of needles being used on more than one client" said Piliang
"We are probably looking at 150,000 being treated this year, maybe slightly more - say 200,000 - next year" Alton said
..."We are going to price this fixed-dose regimen based on those costs," Alton said. "We do plan on launching a better product without having a significant premium."
Gregg Alton, Gilead’s executive vice president for corporate and medical affairs, said: "In developing countries, large-volume generic manufacturing and distribution is widely regarded as a key component in expanding access to medicines."

More Content

All (2136) | News (1545) | Reports (0) | Blogs (558) | Audio/Video (1) | Fact Sheets (12) | Press Releases (13)
sort by: Date | Relevance
Madness star supports hep C charity [Published Media Trust - 23 mins ago]
Research and Markets: Global Hepatitis C Market... [Published Business Wire Health News - 27 mins ago]
One Of The Most Expensive Pills In The World Is... [Published Think Progress - 51 mins ago]
Feds warn of dangerous tattoo ink [Published WCVB.com - 1 hour ago]
Ralph Nader Has Set His Sights On Big Pharma --... [Published Forbes.com - 1 hour ago]
If Achillion's Hep C Nucleotide Isn't Best In C... [Published Seeking Alpha - 1 hour ago]
Anti-ISIS Strikes, Cameron's Plea, Daredevil Gr... [Published Worldcrunch - 2 hours ago]
Gilead to raise price for new hepatitis C drug ... [Published Nile International - 2 hours ago]
Sovaldi deal for developing world ‘falls short’ [Published PMLive - 2 hours ago]
Gilead announces generic licensing agreements w... [Published Manufacturing Chemist - 2 hours ago]
Hepatitis C Market & Forecast, HCV Drugs Clinic... [Published PharmiWeb - 3 hours ago]
Cadila Health up 3%, diabetic drug gets tentati... [Published Moneycontrol.com - 4 hours ago]
NS5A inhibitors useful for treating HCV [Published Free Patents Online - 5 hours ago]
Police say Hep C positive man used syringe in r... [Published NewsMail - 5 hours ago]
Gilead allows generic prices for Sovaldi [Published Pharmafocus - 5 hours ago]
Polynucleotides encoding a human TRIM-Cyp fusio... [Published Free Patents Online - 5 hours ago]
Police officer accused of assaulting a train co... [Published Brisbane Times - 6 hours ago]
Gilead to license generic Sovaldi for poor coun... [Published News-Journal - 6 hours ago]
Cipla enters into non-exclusive licensing agree... [Published Indian-Commodity - 7 hours ago]
Zydus inks pact with Gilead Sciences to produce... [Published Indian-Commodity - 7 hours ago]
Angel Broking remains neutral on Ranbaxy Labs [Published MyIris - 7 hours ago]
Sequent Scientific signs licensing agreement wi... [Published Equity Bulls - 7 hours ago]
Cipla advances on entering into non-exclusive l... [Published Arihant Capital - 8 hours ago]
Access to Hepatitis C Drugs to be Expanded in D... [Published Rediff Realtime News - 8 hours ago]
Could Ebola Become As Contagious As The Flu? [Published New England Public Radio - 8 hours ago]
Business roundup: Mylan reaches deal on hepatit... [Published Pittsburgh Tribune Review - 9 hours ago]
Gilead hands Sovaldi manufacturing tech to 7 ge... [Published FiercePharmaManufacturing - 9 hours ago]
L&T in focus after order win [Published Business Standard India - 9 hours ago]
Market may extend losses [Published Business Standard India - 10 hours ago]
Hope for 'cheap' hepatitis drug [Published Calcutta Telegraph - 11 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Global Hepatitis C Market... [Published Business Wire Health News - 27 mins ago]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/92nqsp/global_hepatitis) has announced the addition of the "Global Hepatitis C Market 2014-2018" report to their offering. The Global Hepatitis C market to grow ...
One Of The Most Expensive Pills In The World Is... [Published Think Progress - 51 mins ago]
Hepatitis C medication Sovaldi CREDIT: AP Photo/Courtesy of Gilead Sciences, File The company that makes one of the most expensive pills the world is attempting to expand access to the medication among low-income people who can’t afford the $1,000 ...
Gilead mulls price of next version of Sovaldi a... [Published Tech Chronicles - 15 hours ago]
The $84,000 price tag of Gilead Sciences’ hepatitis C drug is raising eyebrows in Oregon and beyond, but the Foster City company says that the next generation of the drug may not cost significantly more. Next month, the U.S. Food and Drug Administration ...
Generic Hepatitis C Drug Could Help 100 Million... [Published The Middle East Blog - TIME.com - 17 hours ago]
Gilead Sciences, a drug company that produces a highly effective but also highly expensive hepatitis C treatment, announced a deal on Monday to license its product to other drug companies to make cheaper versions. Sovaldi, which is the name of Gilead’s ...
Generic Hepatitis C Drug Could Help 100 Million... [Published The Curious Capitalist - 17 hours ago]
Gilead Sciences, a drug company that produces a highly effective but also highly expensive hepatitis C treatment, announced a deal on Monday to license its product to other drug companies to make cheaper versions. Sovaldi, which is the name of Gilead’s ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
GM Puts Engineers On Leave [Published Wall Street Journal What's News - Apr 10 2014]
1

Press Releases

sort by: Date | Relevance
Screening and Drug Therapy Predicted to Make He... [Published GlobeNewswire: Advertising News - Aug 05 2014]
U.S. FDA has granted Priority Review for OLYSIO... [Published GlobeNewswire: Advertising News - Jul 15 2014]
European Medicines Agency Validates Marketing A... [Published Financial Services - Jun 17 2014]
OraSure Technologies Announces New Co-Promotion... [Published GlobeNewswire: Advertising News - Jun 11 2014]
OLYSIO™ available soon in all Nordic countries ... [Published GlobeNewswire: Acquisitions News - Jun 10 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.